1. Home
  2. CRESY vs EOLS Comparison

CRESY vs EOLS Comparison

Compare CRESY & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRESY
  • EOLS
  • Stock Information
  • Founded
  • CRESY 1936
  • EOLS 2012
  • Country
  • CRESY Argentina
  • EOLS United States
  • Employees
  • CRESY N/A
  • EOLS N/A
  • Industry
  • CRESY Real Estate
  • EOLS Biotechnology: Pharmaceutical Preparations
  • Sector
  • CRESY Finance
  • EOLS Health Care
  • Exchange
  • CRESY Nasdaq
  • EOLS Nasdaq
  • Market Cap
  • CRESY 664.8M
  • EOLS 589.3M
  • IPO Year
  • CRESY 1997
  • EOLS 2018
  • Fundamental
  • Price
  • CRESY $10.46
  • EOLS $9.51
  • Analyst Decision
  • CRESY
  • EOLS Strong Buy
  • Analyst Count
  • CRESY 0
  • EOLS 5
  • Target Price
  • CRESY N/A
  • EOLS $23.75
  • AVG Volume (30 Days)
  • CRESY 194.2K
  • EOLS 876.1K
  • Earning Date
  • CRESY 09-08-2025
  • EOLS 07-30-2025
  • Dividend Yield
  • CRESY 9.12%
  • EOLS N/A
  • EPS Growth
  • CRESY N/A
  • EOLS N/A
  • EPS
  • CRESY 0.09
  • EOLS N/A
  • Revenue
  • CRESY $648,198,954.00
  • EOLS $275,463,000.00
  • Revenue This Year
  • CRESY N/A
  • EOLS $33.39
  • Revenue Next Year
  • CRESY N/A
  • EOLS $33.21
  • P/E Ratio
  • CRESY $10.44
  • EOLS N/A
  • Revenue Growth
  • CRESY N/A
  • EOLS 25.38
  • 52 Week Low
  • CRESY $6.56
  • EOLS $8.67
  • 52 Week High
  • CRESY $14.23
  • EOLS $17.82
  • Technical
  • Relative Strength Index (RSI)
  • CRESY 40.37
  • EOLS 48.28
  • Support Level
  • CRESY $10.60
  • EOLS $9.45
  • Resistance Level
  • CRESY $11.07
  • EOLS $9.95
  • Average True Range (ATR)
  • CRESY 0.31
  • EOLS 0.34
  • MACD
  • CRESY 0.00
  • EOLS 0.07
  • Stochastic Oscillator
  • CRESY 9.46
  • EOLS 49.47

About CRESY Cresud S.A.C.I.F. y A.

Cresud SACIF y A is engaged in agricultural business and urban properties and investment business. Under its agricultural business the company produces oilseed grains and cereals, sugar cane and meat. The Agricultural business of the company is further comprised of four reportable segments which are Agricultural production, Land transformation and Sales, Corporate and Other segments. The company participates in the real estate business in Argentina through its subsidiary IRSA. The real estate business is further comprised of five reportable segments, namely Shopping Malls, Offices, Sales and Developments, Hotels and others.

About EOLS Evolus Inc.

Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.

Share on Social Networks: